Michael MBA - Champions Oncology Chief Officer
| CSBR Stock | USD 4.31 0.02 0.46% |
Insider
Michael MBA is Chief Officer of Champions Oncology
| Address | One University Plaza, Hackensack, NJ, United States, 07601 |
| Phone | 201 808 8400 |
| Web | https://www.championsoncology.com |
Champions Oncology Management Efficiency
The company has return on total asset (ROA) of (0.0693) % which means that it has lost $0.0693 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.3246) %, meaning that it created substantial loss on money invested by shareholders. Champions Oncology's management efficiency ratios could be used to measure how well Champions Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Equity is likely to grow to 4.01, while Return On Tangible Assets are likely to drop (0.30). At this time, Champions Oncology's Total Assets are relatively stable compared to the past year. As of 11/29/2024, Non Current Assets Total is likely to grow to about 13.1 M, while Intangible Assets are likely to drop slightly above 650.6 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA BS | AN2 Therapeutics | 49 | |
| Casi DeYoung | Shattuck Labs | 53 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Hing Wong | HCW Biologics | 70 | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
| Paul MD | AN2 Therapeutics | 54 | |
| Conor Richardson | Shattuck Labs | N/A | |
| John CPA | MediciNova | N/A | |
| Michael Diem | Century Therapeutics | 53 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Eric Easom | AN2 Therapeutics | 56 | |
| Man MBA | Adagene | 47 | |
| Peter Rhode | HCW Biologics | 66 | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| James JD | Eliem Therapeutics | 58 | |
Management Performance
| Return On Equity | -4.32 | ||||
| Return On Asset | -0.0693 |
Champions Oncology Leadership Team
Elected by the shareholders, the Champions Oncology's board of directors comprises two types of representatives: Champions Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Champions. The board's role is to monitor Champions Oncology's management team and ensure that shareholders' interests are well served. Champions Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Champions Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marianna Zipeto, Research Commercial | ||
| Michael MBA, Chief Officer | ||
| Maria Mancini, Chief Operations | ||
| Karin Heidemann, Executive Operations | ||
| Ronnie MD, CEO Director | ||
| Arthur Hanson, Vice Technology | ||
| BS CMAR, Ex Operations | ||
| David MBA, Chief Officer | ||
| Brady Davis, President | ||
| MBA MS, VP Marketing |
Champions Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Champions Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.32 | ||||
| Return On Asset | -0.0693 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 62.8 M | ||||
| Shares Outstanding | 13.59 M | ||||
| Shares Owned By Insiders | 26.33 % | ||||
| Shares Owned By Institutions | 49.00 % | ||||
| Number Of Shares Shorted | 224.45 K | ||||
| Price To Earning | 220.00 X |
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Champions Stock
| 0.49 | VERV | Verve Therapeutics | PairCorr |
| 0.46 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.36 | EQ | Equillium | PairCorr |
| 0.35 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.